Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Antibody-Based Cancer Immunotherapy
EP. 1: Introduction: Immunotherapy Research Milestones
July 18th 2014
EP. 2: Checkpoint Inhibitors in Metastatic Melanoma
July 18th 2014
EP. 3: Future Role of Checkpoint Inhibitors in Melanoma
July 18th 2014
EP. 4: Checkpoint Inhibitor Combination Strategies
July 18th 2014
EP. 5: Adjuvant Ipilimumab in High-Risk Melanoma
July 18th 2014
EP. 6: PD-L1 Inhibition With MPDL3280A in Bladder Cancer
July 18th 2014
EP. 7: Future Role of Immunotherapy in Cancer
July 18th 2014
EP. 8: Targeted Immunotherapy in Cancer
July 18th 2014
EP. 9: PD-L1 Immunotherapy in Bladder Cancer
July 18th 2014
EP. 10: Evolving Role of PD-L1 as a Biomarker
July 18th 2014
EP. 11: Utility of PD-L1 as a Biomarker in Bladder Cancer
July 18th 2014
EP. 12: Checkpoint Inhibition in Renal Cell Carcinoma
July 18th 2014
EP. 13: Development of Checkpoint Inhibitors for GU Cancers
July 18th 2014
EP. 14: Rini Explores PD-1 Inhibition in Renal Cell Carcinoma
July 18th 2014
EP. 15: Evolving Renal Cell Carcinoma Treatment Paradigm
July 18th 2014
EP. 16: Immune Checkpoint Inhibitors in NSCLC
July 18th 2014
EP. 17: Optimizing Checkpoint Inhibition in NSCLC
July 18th 2014
EP. 18: Sequencing Checkpoint Inhibitors in NSCLC
July 18th 2014
EP. 19: Immunotherapy Combination Strategies in RCC
July 18th 2014
EP. 20: PD-1 Combinations Explored in RCC
July 18th 2014
NEXT PAGE
<
1
2
>
PREVIOUS PAGE
x
